BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 3, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2023

View Archived Issues
Janet Siliciano speaking at podium

HIV cure, a less uncertain journey

HIV research is a winding road where one obstacle leads to another, slowing down success. The first barrier to getting the cure starts before one can even talk about it. “Cure may be too powerful and promising a term. Remission is probably better,” said John Mellors, whose work led to the universal use of plasma HIV-1 RNA and CD4+ T-cell counts in HIV-1 infection.

“Cure means maintaining an undetectable viral load off antiretroviral treatment. That means you cannot transmit it to people. Within that definition, there are people that have complete eradication of every single virus. And then, you have people that have a low level of virus that are able to keep under control without drugs,” Sharon Lewin told BioWorld. “Remission is maintaining a viral load less than 50 copies per milliliter in the absence of any retroviral. But there is still virus detectable,” she explained. Lewin is the director of The Peter Doherty Institute for Infection and Immunity in Melbourne, and the president of the International AIDS Society (IAS). Read More

Medshine Discovery discloses new JAK inhibitors

Medshine Discovery Inc. has patented Janus kinase (JAK) inhibitors reported to be useful for the treatment of inflammatory bowel disease. Read More
Multiple sclerosis

BTK inhibitor GB-7208 shows promise for treating multiple sclerosis relapse

Therapies for multiple sclerosis (MS) have been effective in relapse prevention but emerging data still show the continued disability progression independent of relapse activity (PIRA), characterized by the presence of ectopic B-cell follicles and active lesions with microglia cells, resulting in a smoldering central nervous system (CNS)-driven inflammation, tissue damage and disease progression. Read More
Mast cell releasing histamine during allergic response

EP-262 inhibits agonist-induced mast cell degranulation and vascular permeability in vivo

At the ongoing AAAAI meeting in San Antonio, researchers from Escient Pharmaceuticals Inc. presented preclinical data for the Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist EP-262, being evaluated as a novel therapeutic approach for mast cell-mediated diseases. In vitro, EP-262 acted as a potent and highly selective antagonist of MRGPRX2, which inhibited MRGPRX2 activation induced by a wide variety of agonists. Read More
Gastrointestinal-microbiome

TRIM40 identified as a therapeutic target in inflammatory bowel disease

Researchers from Yonsei University reported their findings from a study that aimed to investigate the mechanisms underlying aberrant actin remodeling in inflammatory bowel disease (IBD). Revision of public gene expression datasets of rectum biopsy samples from patients with IBD identified a subset of patients that exhibited substantially higher levels of tripartite motif-containing protein 40 (TRIM40), a gene that is epigenetically silenced under healthy conditions. Read More
Multiple-sclerosis-damaged-myelin

Bryostatin-1 augments remyelination through its PKC modulator activity

It was previously demonstrated that the CNS-penetrant compound bryostatin-1 (bryo-1) exerts an immunomodulatory effect on myeloid-lineage innate immune cells in the periphery through its actions on protein kinase C (PKC). In a new study, researchers from Johns Hopkins University aimed to assess the potential of bryo-1 for the treatment of progressive multiple sclerosis (MS) by investigating its effect on remyelination. Read More

Eurofarma and Universidade Federal do Rio de Janeiro divulge new SCN9A and/or SCN10A inhibitors

Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have synthesized N-acylhydrazone acting as sodium channel protein type 9 subunit alpha (SCN9A, Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain. Read More
Man scratching arm

SORBS1 gene polymorphism impacts atopic dermatitis risk through milk exposure, study finds

Environmental factors, such as those from food allergens, can modulate IgE-driven hypersensitivity related to the genetics of allergy. Researchers from the Korea National Institute of Health aimed to investigate the impact of polymorphisms in the SORBS1 gene in relation to atopic dermatitis based on milk exposure. Read More

Global Health Drug Discovery Institute describes new SARS-CoV-2 3CLpro inhibitors

Global Health Drug Discovery Institute (GHDDI) has presented 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 infections (COVID-19). Read More

Shanghai Huilun Pharmaceutical patents new DHODH inhibitors

Shanghai Huilun Pharmaceutical Co. Ltd. has identified thiazle derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer, viral infections and autoimmune diseases. Read More
Heart scientific overlay

Actelion Pharmaceuticals discovers new PDGFR inhibitors

Actelion Pharmaceuticals Ltd. has disclosed platelet-derived growth factor receptor beta (PDGFR-β) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 2, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • Illustration of brain with neuron receptor

    5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

    BioWorld Science
    Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing